Form 4: Alumis Inc. Executive Bradley Mark Christopher Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Chief Development Officer Bradley Mark Christopher reports transactions involving Alumis Inc. stock and options, including reclassification of Class A Common Stock and adjustments to holdings through various stock options and GRATs.
Summary
- On July 1, 2024, Bradley Mark Christopher, Chief Development Officer of Alumis Inc., reported changes in his beneficial ownership of the company's securities.
- The reported transactions include the reclassification of Class A Common Stock into voting Common Stock, exempt under Rule 16b-7 and Rule 16b-3.
- Christopher's holdings are also affected by stock option grants and vesting schedules, as well as shares held indirectly through JB 2023 GRAT and MB 2023 GRAT, for which he serves as a trustee.
- The transactions involve multiple stock option grants with varying exercise prices and vesting schedules, extending out to 2034.
- Some options vest based on performance criteria and continued service to the Issuer.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply reports transactions without expressing positive or negative views.
Positives
- The report indicates ongoing equity-based compensation for a key executive, aligning his interests with the company's long-term performance.
Future Outlook
The vesting schedules of the stock options suggest a long-term incentive plan for the executive, tied to continued service and potentially performance milestones.
Industry Context
Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing is typical for executives receiving equity compensation.
Comparison to Industry Standards
- Equity compensation is a common practice in the biotechnology industry to attract and retain talent.
- Vesting schedules and performance-based options are also standard features of executive compensation packages in comparable companies such as Gilead Sciences, Amgen, and Biogen.
- The specific terms of the options, such as exercise price and vesting criteria, would need to be compared to industry benchmarks to assess their competitiveness.
Stakeholder Impact
- Shareholders can use this information to understand the alignment of management's interests with the company's performance.
- The vesting schedules of the options may incentivize the executive to focus on long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 01/27/2023 | 25% of shares underlying one stock option vested. |
| 01/27/2024 | 33% of shares underlying one stock option vested. |
| 05/22/2024 | 25% of shares underlying one stock option vested. |
| 06/27/2024 | Date of earliest transaction; stock option grant. |
| 07/01/2024 | Date of reported transactions; reclassification of stock and option adjustments. |
| 06/21/2025 | 25% of shares underlying one stock option vest. |
| 06/06/2025 | 25% of shares underlying one stock option vest. |
| 05/06/2028 | First vesting date for performance-based stock options. |
| 05/06/2029 | Second vesting date for performance-based stock options. |
| 05/06/2030 | Third vesting date for performance-based stock options. |
| 01/26/2032 | Expiration date for certain stock options. |
| 06/22/2033 | Expiration date for certain stock options. |
| 10/08/2033 | Expiration date for certain stock options. |
| 05/05/2034 | Expiration date for certain stock options. |
| 06/05/2034 | Expiration date for certain stock options. |
| 06/26/2034 | Expiration date for certain stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.